Biomedical Approaches to HIV Prevention HIV Research Catalyst Forum April 21, 2010, Baltimore, MD Monica S. Ruiz, PhD, MPH George Washington University.

Slides:



Advertisements
Similar presentations
HIV/AIDS The Epidemic in ANE and E&E So what do we do now? Paul De Lay Senior Advisor on HIV/AIDS Office of HIV/AIDS.
Advertisements

The Connection Between STDs and HIV
No one left behind: Increased coverage, better programmes and maximum impact for key populations WHO Consolidated Guidelines on HIV Prevention, Diagnosis,
Women and ARV-based Prevention: Challenges and Opportunities Tim Mastro, MD, DTM&H AIDS 2014 Melbourne, Australia 24 July 2014.
Overview of the current evidence on male circumcision and HIV prevention Catherine Hankins Associate Director, Department of Policy, Evidence and Partnerships.
HIV treatment as prevention Stephen Kegg. 2 Learning Outcomes Overview of HIV management HIV transmission risks Current prevention strategies Which new.
PEPFAR Emmanuel Njeuhmeli, MD, MPH, MBA Senior Biomedical Prevention Advisor and Co-Chair PEPFAR Male Circumcision Technical Working Group Office of HIV/AIDS.
Modelling HIV/AIDS in Southern Africa Centre for Actuarial Research (CARe) A Research Unit of the University of Cape Town.
HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.
Hadiyah Charles, Community HIV/AIDS Mobilization Project Naina Khanna, WORLD/U.S. Positive Women’s Network HIV Research Catalyst Forum April 21, 2010.
Does Africa need a rectal microbicide? IRMA and AVAC presentation 27 September 2011 Salim S. Abdool Karim Pro Vice-Chancellor (Research), University of.
Attaining Realistic and Substantial Reductions in HIV Incidence: Model Projections of Combining Microbicide and Male Circumcision interventions in Rural.
HIV/AIDS Prevention and Care Nancy S. Padian, PhD, MPH Professor, Obstetrics, Gynecology & Reproductive Sciences Associate Director for Research, Global.
How well are we doing in preventing HIV and how can we do better?
The Global Response to AIDS: Does It Pass the Test for Women? Peter Piot Institute for Global Health Imperial College.
Epidemiology of HIV and Access to Prevention services, Tanzania Joint Biennial HIV National Response Review Stakeholders meeting. November, 2014 Blue Pearl.
Are people living with HIV less likely to pass HIV to others if they are on treatment? Exploring the use of treatment as prevention James Wilton Project.
The potential and challenges of ARV-based HIV prevention: An overview
Prevention Trials in the Region Behavioral Trials* Author (Year) LocationIntervention Findings (Rate ratio (RR)) Ross (2007) Tanzania MEMA kwa Vijana,
Midwest AIDS Training & Education Center Health Care Education & Training, Inc. HIV/AIDS Case-Finding In Family Planning Clinics.
SRH/HIV Linkages: What’s The Rationale? Ward Cates, MD, MPH Family Health International World Bank Washington, DC November 19, 2008.
Microbicide Research: A Promising HIV/AIDS Prevention Strategy for Women Roberta Black, Ph.D. Division of AIDS, National Institute of Allergy and Infectious.
Creating an AIDS-Free Generation The beginning of the end of AIDS Center for Strategic & International Studies Washington, DC March 22, 2012 Thomas R.
EngenderHealth/UNFPA Project – Ethiopia/Ukraine Strengthening the integration of HIV prevention in maternal health services. Increasing the capacity of.
Women and Children The challenges of HIV/AIDS By Mabel Bianco MD, MPH Epidemiologist International Womens Health Coalition FEIM / IAWC Mexico, July 2008.
Introduction to HIV New Prevention Technologies (NPTs)
LIMPOPO PROVINCIAL MEN’S SECTORS/BROTHERS FOR LIFE PRESENTED BY: RAPAKWANA JOHANNAH MANAGER:GAAP in HIV & AIDS & STIs Directorate DEPT OF HEALTH AND SOCIAL.
Prevention of Mother to Child Transmission of HIV
Comprehensive HIV Prevention Strategies for Most at Risk Populations (MARPs) Anne Goldzier Thomas, Ph.D. US Department of Defense/PEPFAR Ethiopia National.
Summarising Male Circumcision Efficacy: Results of the three randomised clinical trials Neil A Martinson Perinatal HIV Research Unit.
Cindra Feuer and Marc-André LeBlanc HRCF, 21 April 2010 ARV-based Prevention.
October 8, 2010 USAID Mini-University Clancy Broxton, MA, MPH Most At Risk Populations Advisor USAID Office of HIV/AIDS HIV Prevention for Most At- Risk.
Microbicide research in Africa: Partnership in Action Salim S. Abdool Karim, MD, PhD Director: CAPRISA Pro Vice-Chancellor (Research): University of KwaZulu-Natal.
Male Circumcision and HIV prevention, the Evidence and potential Impact on HIV incidence in Zimbabwe Karin Hatzold, MD, MPH Director HIV Services PSI Zimbabwe.
The HIV virus. The overwhelming majority of people with HIV live in low- and middle-income countries. Sub- Saharan Africa accounts for two-thirds.
Myron S. Cohen, MD Associate Vice Chancellor Director, Institute for Global Health The University of North Carolina.
Microbicide and PrEP Overview GCM Adolescent Consultation Durban, South Africa 5-6 Sept, 2007 Craig M. Wilson Adolescent Medicine Trials Network for HIV/AIDS.
Cost-effectiveness of male circumcision in reducing the spread of HIV in the general population in sub-Saharan Africa Jim Kahn & Elliot Marseille, UCSF.
TRACK C RAPPORTEURS REPORT. Prepared by Anne BuvéBelgium Anne BuvéBelgium Sabina Bindra-BarnesIndia Sabina Bindra-BarnesIndia Saidi KapigaTanzania Saidi.
Office of Global Health and HIV (OGHH) Office of Overseas Programming & Training Support (OPATS) Session: Voluntary Medical Male Circumcision (VMMC)
National Working Group on Microbicides The Basics of Microbicides Amitrajit Saha PATH January 2007.
Human Sexuality Sexually Transmitted Infections. STIs/STDs Sexually Transmitted Infections: More accurate than “STDs” A less judgmental term?
HIV Prevention : Why we need more options for women Wanjiku Kamau Consultant: International AIDS Vaccine Initiative Consultant: International Partnership.
HIV-infected subjects with CD4 350 to 550 cells/mm serodiscordant couples HPTN 052 Study Design Immediate ART CD Delayed ART CD4
Exploring the potential impact of ART in reducing HIV transmission. Geoff Garnett, Jeff Eaton, Tim Hallett & Ide Cremin Imperial College London.
FBO Engagement in Male Circumcision May 25, 2009 CCIH Annual Conference.
“AIDS has a woman’s face” -In Sub-Saharan Africa, nearly 60% of people living with HIV/AIDS are women -Teenage girls in parts of.
HIV/AIDS and Gender: South African Women and the Spread of Infection.
Prevention trials pipeline MOSY3. Willard Cates, HIV Prevention Research: The Optimist’s.
Global SRH/HIV Integration National HIV Prevention Conference “Integration of Services: National and International Perspectives” Atlanta, GA August 24,
IAS July 1 The Caprisa 004 result in context Sheena McCormack Clinical Scientist MRC Clinical Trials Unit.
HIV/AIDS IN AFRICA- "The Orphaned Continent"
New ARV-based prevention tools how the research is happening how we need to be involved Anna Forbes, MSS Consultant, HIV and women’s health HIV Research.
New Prevention Technologies Workshop Module 2: NPTs in context
Antiretrovirals for HIV Prevention: Progress and Challenges Kenneth H. Mayer, M.D. Brown/Miriam/Fenway.
HIV Prevention: A Winnable Battle Centers for Disease Control and Prevention.
HIV and Women Collaborating Across Borders to Advance the Health of Women IAS 2012 Gina M. Brown, M.D. July 22, 2012.
N ORTHWEST AIDS E DUCATION AND T RAINING C ENTER HIV Prevention in Clinical Care Settings Jeanne Marrazzo, MD, MPH Professor, Division of Allergy and Infectious.
Overview of Current Research on HIV Prevention Technologies and Implementation Challenges Quarraisha Abdool Karim, PhD Co-PI HPTN PLG Associate Scientific.
INITIATIVES OF HIGH LEVEL TASKFORCE FOR WOMEN, GIRLS, GENDER EQUALITY AND HIV FOR EASTERN AND SOUTHERN AFRICA TACAIDS.
Prevention Science Gaps and the HIV/AIDS Pandemic Quarraisha Abdool Karim, PhD Head: CAPRISA Women and AIDS Pogramme Associate Professor in Epidemiology,
COST, IMPACT and CHALLENGES of ACCELERATED SCALE-UP
Information about HIV Prevention Options
IAS Satellite Session 25th July 2017 Daniel Were, PhD
On behalf of The MTN-020/ASPIRE Study Team
COMBINATION PREVENTION
Prevention Trials in the Region Behavioral Trials*
A public cervix announcement: CERVICAL BARRIERS in seven minutes
HIV/AIDS Prevention and Care
HIV.
Presentation transcript:

Biomedical Approaches to HIV Prevention HIV Research Catalyst Forum April 21, 2010, Baltimore, MD Monica S. Ruiz, PhD, MPH George Washington University School of Public Health and Health Services

HIV Prevention Strategies Infected Person (transmission & disease progression) Susceptible Person (acquisition) Treatment of Addiction NEP/SEP PMTCT Microbicide Treatment of STD and OI Treatment of Addiction NEP/SEP STD Treatment PMTCT Microbicide VCT Behavioral Risk Reduction ART VCT Behavioral Risk Reduction Vaccine PEP PrEP Male Circumcision

 Decrease susceptibility to HIV by:  Reducing risk of exposure to the virus  If exposed, reduce risk of the virus “taking hold”  Decrease infectiousness of HIV by:  Reducing viral load  Reducing the other biological factors (e.g., infections) that increase transmission risk Biomedical & Technological Interventions

 Male, latex condoms are 80% to 95% effective in reducing the risk of HIV transmission when used consistently and correctly  Female condoms are estimated to be between 94% and 97% effective in reducing risk of STI, including HIV, transmission when used consistently and correctly Condoms References: NIH, 2001; Hearst & Chen 2003; Weller & Davis 2004; Holmes, et al. 2004; Trussell et al

 Long- and short-course AZT and single-dose NVP are effective in reducing MTCT by 44% to 66%  Breast-milk substitutes have been shown to significantly reduce infection among infants.  The number of children who acquired HIV perinatally decreased by 89% between 1992 and 2001 Preventing Mother-to-Child Transmission Sources: Brocklehurst 2004; Cooper et al

Male Circumcision Two meta-analyses of observational studies found the risk of acquiring HIV among circumcised men was about half that of uncircumcised men. Data from three RCTs showed that circumcision has a significant protective effect against HIV acquisition South Africa: 61% protective Kenya: 53% protective Uganda: 48% protective Sources: Weiss, et al. 2000; Siegfried, et al. 2004; Auvert, et al. 2005; Bailey et al., 2007; Gray et al., 2007

Cervical Barrier Methods  The cervix may be particularly vulnerable to HIV and STI transmission.  The MIRA trial found that there was no added protective benefit from the diaphragm.  But the trial was not designed to determine whether the use of the cervical barrier was better than nothing at all.  Other cervical barriers, when combined with an effective microbicide, may be more successful in preventing HIV infection Sources: Padian et al., 2007

HIV Lactobacillus Vaginal epithelium physical barrier lubrication Maintenance of normal microflora Viral disruption/inactivation Prevention of other STDs Microbicides

Microbicide Trial results to date Study NameSponsorPopulation Microbicide candidate(s) being tested Findings HPTN 035NIH 3,099 women from sites in Malawi, South Africa,US, Zambia and Zimbabwe. BufferGel & PRO % efficacy for PRO 2000 (NS) No observed efficacy for BufferGel CarraguardPopulation Council, USAID, BMGF 6,202 women from 3 sites in South Africa CarraguardNo observed efficacy Cellulose Sulfate CONRAD, USAID, BMGF 1398 women from sites in African and India Cellulose Sulfate More observed infections in the CS group than placebo (NS) Trial stopped early for fear of harm

Vaccines

X X

 STIs increase susceptibility to HIV infection.  Having HSV-2 infection (genital herpes) is associated with 3x higher risk of HIV acquisition.  HSV-2 can also increase infectiousness of HIV+.  STI management may be most effective in populations with concentrated sexually transmitted HIV epidemics and in populations with high prevalence of STIs and sexual risk behaviors Treatment and Management of Sexually Transmitted Infections Freeman et al. 2006; Grosskurth et al. 1995; Wawer, et al 1999; Kamali, et al 2003; Korenromp et al Sources: Freeman et al. 2006; Grosskurth et al. 1995; Wawer, et al 1999; Kamali, et al 2003; Korenromp et al

HSV-2 Trial Results Two trials of HSV-2 treatment in HIV-uninfected persons showed no protective effect against HIV acquisition One trial of HSV-2 treatment among HIV+ persons showed no evidence of reducing rates of HIV transmission Mixed results re: the impact of HSV-2 treatment on genital HIV shedding, viral load levels, genital HSV shedding, etc.

Post-Exposure Prophylaxis (PEP) A short course of ART taken within 72 hours of exposure can be effective in preventing HIV infection A short course of ART taken within 72 hours of exposure can be effective in preventing HIV infection One study of occupational PEP found that AZT taken within 24 hrs. of exposure and over 28 days reduced HIV acquisition by 81% One study of occupational PEP found that AZT taken within 24 hrs. of exposure and over 28 days reduced HIV acquisition by 81% Cardo et al. 1997; Wulfsohn 2003; Mayer Sources: Cardo et al. 1997; Wulfsohn 2003; Mayer 2003.

Pre-Exposure Prophylaxis (PrEP)

Many difficult questions are associated with PrEP

Ongoing PrEP Trials Source:

Biomedical strategies are only one piece of the prevention puzzle Behavioral, social, and structural interventions are important too! It is not likely that any one intervention will be 100% effective. We must not confuse lack of implementation with lack of effectiveness. So what do we know?

Other important factors that must be considered in HIV prevention Psychological, social, economic, and cultural dynamics of gender and sexuality New and changing context for both sexual and substance use behavior Differences in the perceived consequences of HIV infection Social, structural, environmental factors and contexts that contribute to the HIV/AIDS epidemic

Infected Person (transmission & disease progression) Susceptible Person (acquisition) Rx Addiction NEP/SEP Perinatal Microbicide Rx HIV Rx STD Rx OI Rx Addiction NEP/SEP Rx STD Perinatal Microbicide VCT Behavioral Risk Reduction ART VCT Behavioral Risk Reduction Vaccine PEP/PREP Access to & Delivery of Prevention Services -- scaling up effective programs -- financing prevention services Stigma & Discrimination/ Social Support -- policies -- customs -- norms -- institutions Social Equity/Inequality -- race/ethnicity -- sex/gender -- age -- immigration/citizenship -- class/income/wealth Social Stability/Instability -- war -- violence -- migration -- famine

Thank you for your attention!